Opthea to Present at Jefferies London Healthcare Conference
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that CEO Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on November 15, 2022, at 7:25 AM GMT (6:25 PM AEDT). The presentation will be accessible via a live audio webcast for 90 days on Opthea's Investors page. The company focuses on developing therapies for retinal diseases such as wet AMD and diabetic macular edema. Its lead product, OPT-302, is currently in Phase 3 clinical trials aimed at enhancing treatment efficacy when used with anti-VEGF-A therapies.
- None.
- None.
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT (6:25 PM AEDT).
The live audio will be webcast and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.
About Opthea Limited
Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Inherent risks of Investment in Biotechnology Companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
Authorized for release to ASX by Megan Baldwin, CEO & Managing Director
| Company & Media Enquiries: | |||
| U.S.A. & International: | Australia: | ||
| Sam Martin | Rudi Michelson | ||
| Argot Partners | Monsoon Communications | ||
| Tel: +1-212-600-1902 | Tel: +61 (0) 3 9620 3333 | ||
| opthea@argotpartners.com | |||
| Media: | |||
| Silvana Guerci-Lena | |||
| NorthStream Global Partners | |||
| Tel: +1-973-509-4671 | |||
| silvana@nsgpllc.com | |||
| Join our email database to receive program updates: | |||
| Tel: +61 (0) 3 9826 0399 | Email: info@opthea.com | Web: www.opthea.com | |
FAQ
When will Opthea Limited present at the Jefferies London Healthcare Conference?
Where can I watch the Opthea Limited presentation live?
What is the focus of Opthea Limited's product development?
What is OPT-302 and its current status?
What is the goal of using OPT-302 with anti-VEGF-A therapies?
